Your email has been successfully added to our mailing list.

×
0.0069444444444443 0.0069444444444443 0.0069444444444443 0.0069444444444443 0.00687499999999986 -0.0208333333333334 -0.0208333333333334 -0.0416666666666667
Stock impact report

Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting

Marinus Pharmaceuticals, Inc. (MRNS) 
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.marinuspharma.com/investor-relations
Company Research Source: GlobeNewswire
RADNOR, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that results from its Phase 2 trial of ganaxolone in Refractory Status Epilepticus (RSE) were presented at the Neurocritical Care Society 17th Annual Meeting in Vancouver, BC. The results were featured in an oral platform presentation by Henri Vaitkevicius M.D., investigator in the study.  As previously disclosed, ganaxolone met the primary endpoint in the study with none of the 17 patients progressing to IV anesthetics within 24 hours of treatment initiation. A target dose of ganaxolone has been identified for advancement to Phase 3 and this is supported by pharmacokinetic (PK) data, presented for the first time at the meeting today. The newly presented PK data show that the target dose of ganaxolone (7 Show less Read more
Impact Snapshot
Event Time:
MRNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
MRNS alerts

from News Quantified
Opt-in for
MRNS alerts

from News Quantified